跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 24 天前AI 评分35

计提 19 亿美元减值后,Novartis 仍坚持 120 亿美元收购 Avidity Biosciences

After $1.9B impairment hit, Novartis stands by $12B bet on Avidity

AI 导读

Novartis CEO Vas Narasimhan 表示,对 Avidity Biosciences 的 120 亿美元收购“完全在轨”。此前 Novartis 披露 19 亿美元减值,Narasimhan 仍坚持这笔交易。

正文

No­var­tis’ $12 bil­lion ac­qui­si­tion of Avid­i­ty Bio­sciences “re­mains ab­solute­ly on track,” CEO Vas Narasimhan said, af­ter the com­pa­ny dis­closed a $1.9 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news